BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 27009937)

  • 1. The Impact of Mismatch Repair Status in Colorectal Cancer on the Decision to Treat With Adjuvant Chemotherapy: An Australian Population-Based Multicenter Study.
    He EY; Hawkins NJ; Mak G; Roncolato F; Goldstein D; Liauw W; Clingan P; Chin M; Ward RL
    Oncologist; 2016 May; 21(5):618-25. PubMed ID: 27009937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microsatellite instability in mismatch repair proficient colorectal cancer: clinical features and underlying molecular mechanisms.
    Xu Y; Liu K; Li C; Li M; Zhou X; Sun M; Zhang L; Wang S; Liu F; Xu Y
    EBioMedicine; 2024 May; 103():105142. PubMed ID: 38691939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In-depth Clinical and Biological Exploration of DNA Damage Immune Response as a Biomarker for Oxaliplatin Use in Colorectal Cancer.
    Malla SB; Fisher DJ; Domingo E; Blake A; Hassanieh S; Redmond KL; Richman SD; Youdell M; Walker SM; Logan GE; Chatzipli A; Amirkhah R; Humphries MP; Craig SG; McDermott U; Seymour MT; Morton DG; Quirke P; West NP; Salto-Tellez M; Kennedy RD; Johnston PG; Tomlinson I; Koelzer VH; Campo L; Kaplan RS; Longley DB; Lawler M; Maughan TS; Brown LC; Dunne PD;
    Clin Cancer Res; 2021 Jan; 27(1):288-300. PubMed ID: 33028592
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of Deep Learning to Evaluate Tumor Microenvironmental Features for Prediction of Colon Cancer Recurrence.
    Sinicrope FA; Nelson GD; Saberzadeh-Ardestani B; Segovia DI; Graham RP; Wu C; Hagen CE; Shivji S; Savage P; Buchanan DD; Jenkins MA; Phipps AI; Swallow C; LeMarchand L; Gallinger S; Grant RC; Pai RK; Sinicrope SN; Yan D; Shanmugam K; Conner J; Cyr DP; Kirsch R; Banerjee I; Alberts SR; Shi Q; Pai RK
    Cancer Res Commun; 2024 May; 4(5):1344-1350. PubMed ID: 38709069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicopathological features and prognoses in younger and older patients with mismatch repair defects colorectal cancer: a retrospective comparative cohort study.
    Zhang J; Li S; Ma P; Zhang J; Cao Y; Liu C; Zhang X; Li Z; Li C; Zhao Y
    J Gastrointest Oncol; 2024 Feb; 15(1):260-270. PubMed ID: 38482236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world prevalence of microsatellite instability testing and related status in women with advanced endometrial cancer in Europe.
    Kelkar SS; Prabhu VS; Zhang J; Ogando YM; Roney K; Verma RP; Miles N; Marth C
    Arch Gynecol Obstet; 2024 Jun; 309(6):2833-2841. PubMed ID: 38634898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II trial of domatinostat (4SC-202) in combination with avelumab in patients with previously treated advanced mismatch repair proficient oesophagogastric and colorectal adenocarcinoma: EMERGE.
    Cartwright E; Slater S; Saffery C; Tran A; Turkes F; Smith G; Aresu M; Kohoutova D; Terlizzo M; Zhitkov O; Rana I; Johnston EW; Sanna I; Smyth E; Mansoor W; Fribbens C; Rao S; Chau I; Starling N; Cunningham D
    ESMO Open; 2024 Apr; 9(4):102971. PubMed ID: 38518549
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Prognostic Role of Mismatch Repair Status and CDX-2 Expression with Inflammatory Markers and Pathological Risk Factors in Stage II and III Colon Cancer: Multicenter Real-Life Data.
    Aydin SG; Olmez OF; Selvi O; Geredeli C; Ozden F; Bilici A; Acikgoz O; Karci E; Kutlu Y; Hamdard J; Aydin A
    J Gastrointest Cancer; 2024 Mar; 55(1):227-236. PubMed ID: 37347353
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved Risk-Stratification Scheme for Mismatch-Repair Proficient Stage II Colorectal Cancers Using the Digital Pathology Biomarker QuantCRC.
    Wu C; Pai RK; Kosiorek H; Banerjee I; Pfeiffer A; Hagen CE; Hartley CP; Graham RP; Sonbol MB; Bekaii-Saab T; Xie H; Sinicrope FA; Patel B; Westerling-Bui T; Shivji S; Conner J; Swallow C; Savage P; Cyr DP; Kirsch R; Pai RK
    Clin Cancer Res; 2024 May; 30(9):1811-1821. PubMed ID: 38421684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Panel-Based Mutational Signature of Mismatch Repair Deficiency is Associated With Durable Response to Pembrolizumab in Metastatic Castration-Resistant Prostate Cancer.
    Boiarsky D; Gulhan DC; Savignano H; Lakshminarayanan G; McClure HM; Silver R; Hirsch MS; Sholl LM; Choudhury AD; Ananda G; Park PJ; Tewari AK; Berchuck JE
    Clin Genitourin Cancer; 2024 Apr; 22(2):558-568.e3. PubMed ID: 38342659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Challenges in the management of stage II colon cancer.
    Dotan E; Cohen SJ
    Semin Oncol; 2011 Aug; 38(4):511-20. PubMed ID: 21810510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Microsatellite Instability in Sporadic Colorectal Malignancy: A Pilot Study from Northern India.
    Chauhan S; Kumar S; Singh P; Husain N; Masood S
    Asian Pac J Cancer Prev; 2021 Jul; 22(7):2279-2288. PubMed ID: 34319053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mismatch repair status and surgical approach in apparent early-stage endometrial cancer.
    Morton R; Webb PM; Na R; Obermair A; Farrell R
    Int J Gynecol Cancer; 2024 Apr; 34(4):535-543. PubMed ID: 38431289
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Creation of a Quality Payment Program Measure for Mismatch Repair or Microsatellite Instability Biomarker Testing Status in Colorectal, Endometrial, Gastroesophageal, or Small Bowel Carcinoma.
    Bocsi GT; Laudadio J; Jain R; Eakin SM; Bhalla A; Rosenberg JA; Maratt JK; Kupfer SS; Leiman DA; Cardona DM
    Arch Pathol Lab Med; 2024 Jun; 148(6):728-734. PubMed ID: 37708308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cholecystectomy and the risk of colorectal cancer by tumor mismatch repair deficiency status.
    Shang J; Reece JC; Buchanan DD; Giles GG; Figueiredo JC; Casey G; Gallinger S; Thibodeau SN; Lindor NM; Newcomb PA; Potter JD; Baron JA; Hopper JL; Jenkins MA; Win AK
    Int J Colorectal Dis; 2016 Aug; 31(8):1451-7. PubMed ID: 27286977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic and Predictive Value of Immunoscore in Stage III Colorectal Cancer: Pooled Analysis of Cases From the SCOT and IDEA-HORG Studies.
    Domingo E; Kelly C; Hay J; Sansom O; Maka N; Oien K; Iveson T; Saunders M; Kerr R; Tomlinson I; Edwards J; Harkin A; Nowak M; Koelzer V; Easton A; Boukovinas I; Moustou E; Messaritakis I; Chondrozoumaki M; Karagianni M; Pagès F; Arnoux F; Lautard C; Lovera Y; Boquet I; Catteau A; Galon J; ; Souglakos I; Church DN
    J Clin Oncol; 2024 Mar; ():JCO2301648. PubMed ID: 38484206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Microsatellite instability is highly prevalent in older patients with colorectal cancer.
    Jakob D; Orth V; Gödde D; Zirngibl H; Ambe PC
    Front Surg; 2024; 11():1288061. PubMed ID: 38601878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant Chemotherapy for Older Patients With Stage III Colorectal Cancer: A Real-World Analysis of Treatment Recommendations, Treatment Administered and Impact on Cancer Recurrence.
    Piercey O; Wong HL; Leung C; To YH; Heong V; Lee M; Tie J; Steel M; Yeung JM; McCormick J; Gibbs P; Wong R
    Clin Colorectal Cancer; 2024 Mar; 23(1):95-103.e3. PubMed ID: 38242766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Physicians' beliefs about the benefits and risks of adjuvant therapies for stage II and stage III colorectal cancer.
    Wong AC; Stock S; Schrag D; Kahn KL; Salz T; Charlton ME; Rogers SO; Goodman KA; Keating NL
    J Oncol Pract; 2014 Sep; 10(5):e360-7. PubMed ID: 24986112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adding immunotherapy to first-line treatment of advanced and metastatic endometrial cancer.
    Bogani G; Monk BJ; Powell MA; Westin SN; Slomovitz B; Moore KN; Eskander RN; Raspagliesi F; Barretina-Ginesta MP; Colombo N; Mirza MR
    Ann Oncol; 2024 May; 35(5):414-428. PubMed ID: 38431043
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.